Contents

1 New Drug Development .................................................. 1
  1.1 Introduction ......................................................... 1
  1.2 Origin and Goals of the Book ...................................... 2
  1.3 The Discipline of Statistics ....................................... 2
  1.4 A Lifecycle Perspective on Drug Development .................. 3
  1.5 Design, Conduct, and Analysis ................................. 4
    1.5.1 Compelling Evidence ........................................ 4
  1.6 Drug Discovery ..................................................... 4
  1.7 Nonclinical Development Programs .............................. 5
  1.8 Clinical Development Programs ................................. 5
    1.8.1 Ethical Conduct .............................................. 6
    1.8.2 Different Studies in a Clinical Development Program .... 7
  1.9 Manufacturing ...................................................... 8
  1.10 Definitions of Clinical Research and Clinical Trials ........ 9
    1.10.1 Clinical Research ....................................... 9
    1.10.2 Clinical Trials ......................................... 10
  1.11 Operational Execution ........................................... 10
  1.12 The Central Importance of Biological Considerations ....... 10

2 The Regulatory Environment ......................................... 11
  2.1 Introduction ....................................................... 11
    2.1.1 Goals of the ICH ....................................... 12
  2.2 The Food and Drug Administration ............................. 12
    2.2.1 The Code of Federal Regulations ......................... 13
  2.3 cGMP, cGLP, and cGCP .......................................... 14
  2.4 Regulatory Aspects of New Drug Development .................. 14
  2.5 Sponsor and Regulatory Agency Responsibilities ............. 15
  2.6 The Investigational New Drug Application ...................... 15
    2.6.1 Review of the Investigational New Drug Application ...... 17
4.4.2 Exploratory Toxicology Studies ............. 40
4.4.3 Pre-FIH Regulatory Toxicology Studies .......... 41
4.4.4 Post-FIH Regulatory Toxicology Studies .......... 41
4.4.5 Dose Range-Finding Toxicology ................. 41
4.4.6 Genotoxicity .................................. 42
4.5 Assessment of QT Interval Prolongation .......... 42
4.5.1 Long QT Syndrome: Underlying Molecular Biology ........................................ 43
4.5.2 Drug-Induced QT Interval Prolongation ........ 44
4.5.3 Associated Nonclinical Testing .................. 45
4.5.4 Short QT Syndrome ............................ 45

Further Readings .................................... 46

5 Designing Clinical Trials ........................ 47
5.1 Introduction ................................... 47
5.2 Classification of Clinical Trials .................. 47
5.3 Human Pharmacology Trials ..................... 49
5.4 Clinical Pharmacokinetics and Pharmacodynamics .... 51
5.4.1 Pharmacokinetic Parameters .................... 52
5.4.2 Fasting and Fed Pharmacokinetics ............... 52
5.4.3 Absorption and Bioavailability .................. 53
5.4.4 Distribution .................................. 54
5.4.5 Metabolism .................................. 54
5.4.6 Elimination/Clearance ......................... 55
5.5 Therapeutic Exploratory Trials .................... 55
5.6 Therapeutic Confirmatory Trials ................... 56
5.7 Therapeutic-Use Trials ................................ 56
5.8 Study Design .................................... 56
5.9 Ethical Aspects of Design ......................... 57
5.10 Study Design in Drug Clinical Trials ............... 57
5.10.1 The Parallel Group Design ..................... 58
5.10.2 The Cross-over Design ....................... 59
5.10.3 Respective Advantages of the Parallel Group and Cross-over Designs ................. 59
5.10.4 Focus on the Parallel Group Design in This Book ........................................ 60
5.11 Central Principles of Experimental Design in Clinical Trials ........................ 60
5.11.1 Replication .................................. 61
5.11.2 Randomization ................................ 61
5.11.3 Local Control ................................ 64
5.11.4 Good Design Simplifies and Validates the Accompanying Analyses ................. 64
5.11.5 Sample Size Estimation ....................... 65
5.12 The Clinical Study Protocol ........................................ 65
  5.12.1 Inclusion and Exclusion Criteria ............................. 66
  5.12.2 The Primary Objective ........................................ 66
  Further Readings .......................................................... 67

6 Conducting Clinical Trials I: Experimental Methodology .......... 69
  6.1 Introduction ........................................................... 69
  6.2 Blood Pressure Measurement in Clinical Trials .................. 70
    6.2.1 Hypertension .................................................... 70
    6.2.2 Surrogate Endpoints in Clinical Trials ...................... 71
    6.2.3 Arterial Blood Pressure ........................................ 72
    6.2.4 Assessing Blood Pressure Change over Time ................ 73
    6.2.5 A Cautionary Tale: Blood Pressure Measurement at Your Doctor’s Office ........................................ 74
    6.2.6 A Cautionary Tale for Clinical Trial Blood Pressure Measurements .................................................. 75
  6.3 Central Labs ............................................................ 75
    6.3.1 Operational Considerations .................................. 76
  6.4 Core ECG Labs ......................................................... 77
  6.5 The Case Report Form ................................................ 77
  Further Readings .......................................................... 78

7 Conducting Clinical Trials II: Operational Execution ............ 79
  7.1 Introduction ........................................................... 79
  7.2 The Outsourcing Process ............................................. 80
  7.3 Feasibility Evaluations .............................................. 80
    7.3.1 More Extensive Feasibility Evaluations ...................... 81
    7.3.2 Feasibility Reporting ............................................ 82
  7.4 Standard Operating Procedures .................................... 82
    7.4.1 Balancing the Degree of Flexibility Within an SOP ........ 83
    7.4.2 The Necessity of Implementing and Maintaining SOPs .......... 83
  7.5 Project Management ................................................... 84
  7.6 Site and Investigator Recruitment ................................ 85
    7.6.1 Principal Investigators ......................................... 85
    7.6.2 Responsibilities of Principal Investigators .................. 86
    7.6.3 Potential Principal Investigators in Private Practice Settings .................................................. 86
    7.6.4 Potential Principal Investigators at Larger Medical Institutions .................................................. 86
    7.6.5 Principal Investigator Training ................................ 87
  7.7 Subject Recruitment and Retention ................................ 88
    7.7.1 Subject Recruitment ............................................. 88
    7.7.2 Subject Retention ................................................. 89
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.8</td>
<td>Monitoring Clinical Trials</td>
<td>90</td>
</tr>
<tr>
<td>7.9</td>
<td>Data Management</td>
<td>91</td>
</tr>
<tr>
<td>7.9.1</td>
<td>Data Management Plans</td>
<td>91</td>
</tr>
<tr>
<td>7.9.2</td>
<td>Electronic Data Capture</td>
<td>92</td>
</tr>
<tr>
<td>7.9.3</td>
<td>Database Development</td>
<td>92</td>
</tr>
<tr>
<td>7.10</td>
<td>A New Paradigm: Allying With Sponsors</td>
<td>93</td>
</tr>
<tr>
<td>7.11</td>
<td>Underperforming and Non-performing Clinical Trial Sites</td>
<td>93</td>
</tr>
<tr>
<td>7.11.1</td>
<td>Limitations of the Current Model</td>
<td>95</td>
</tr>
<tr>
<td>7.12</td>
<td>Another New Paradigm: The Site-Specific CRO</td>
<td>95</td>
</tr>
<tr>
<td>7.12.1</td>
<td>Synergies of a Sponsor CRO and a Site-Specific CRO Working Together</td>
<td>96</td>
</tr>
<tr>
<td>Further Readings</td>
<td>97</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Statistical Analysis</td>
<td>99</td>
</tr>
<tr>
<td>8.1</td>
<td>Introduction</td>
<td>99</td>
</tr>
<tr>
<td>8.2</td>
<td>Types of Clinical Data</td>
<td>100</td>
</tr>
<tr>
<td>8.2.1</td>
<td>Numerical Variables</td>
<td>100</td>
</tr>
<tr>
<td>8.2.2</td>
<td>Categorical Variables</td>
<td>100</td>
</tr>
<tr>
<td>8.2.3</td>
<td>Parametric Tests and Nonparametric Tests</td>
<td>101</td>
</tr>
<tr>
<td>8.3</td>
<td>Descriptive Statistics: Summarizing Data</td>
<td>101</td>
</tr>
<tr>
<td>8.3.1</td>
<td>Measures of Central Tendency</td>
<td>101</td>
</tr>
<tr>
<td>8.3.2</td>
<td>Measures of Dispersion Around a Central Value</td>
<td>102</td>
</tr>
<tr>
<td>8.4</td>
<td>Inferential Statistics: Hypothesis Testing</td>
<td>103</td>
</tr>
<tr>
<td>8.4.1</td>
<td>The Search for Compelling Evidence</td>
<td>103</td>
</tr>
<tr>
<td>8.4.2</td>
<td>Variation and Systematic Variation</td>
<td>103</td>
</tr>
<tr>
<td>8.4.3</td>
<td>Between-Groups Variation and Within-Groups Variation</td>
<td>104</td>
</tr>
<tr>
<td>8.4.4</td>
<td>Comparing Between-Groups Variance and Within-Groups Variance</td>
<td>104</td>
</tr>
<tr>
<td>8.4.5</td>
<td>The Term Error Does Not Imply a Mistake</td>
<td>105</td>
</tr>
<tr>
<td>8.5</td>
<td>Probability</td>
<td>105</td>
</tr>
<tr>
<td>8.5.1</td>
<td>Likely Events Do Not Always Happen</td>
<td>106</td>
</tr>
<tr>
<td>8.5.2</td>
<td>Clinical Decision-Making</td>
<td>106</td>
</tr>
<tr>
<td>8.5.3</td>
<td>Sampling Theory</td>
<td>107</td>
</tr>
<tr>
<td>8.5.4</td>
<td>The Standard Error of the Mean</td>
<td>107</td>
</tr>
<tr>
<td>8.6</td>
<td>The Normal Distribution</td>
<td>108</td>
</tr>
<tr>
<td>8.6.1</td>
<td>Area Under the Normal Curve</td>
<td>110</td>
</tr>
<tr>
<td>8.6.2</td>
<td>Various Areas Under the Normal Curve</td>
<td>111</td>
</tr>
<tr>
<td>8.7</td>
<td>Analysis of Association</td>
<td>111</td>
</tr>
<tr>
<td>8.7.1</td>
<td>Direction of an Association</td>
<td>112</td>
</tr>
<tr>
<td>8.7.2</td>
<td>Degree of Closeness of an Association</td>
<td>112</td>
</tr>
<tr>
<td>8.7.3</td>
<td>Correlation Coefficients</td>
<td>112</td>
</tr>
<tr>
<td>8.7.4</td>
<td>Determining the Significance of a Product Moment Coefficient</td>
<td>113</td>
</tr>
</tbody>
</table>
8.7.5 The Coefficient of Determination ...................... 113
8.7.6 Association Does Not Necessarily Equate
to Causation ........................................ 114

9 Statistical Significance ........................................ 115
9.1 Introduction .............................................. 115
9.2 Creating a Research Question and Associated Hypotheses .... 115
  9.2.1 The Research Hypothesis ................................ 115
  9.2.2 The Null Hypothesis .................................... 116
9.3 Precise Expression of the Research Hypothesis and the
   Null Hypothesis: The Concept of Statistical Significance .... 116
9.4 Hypothesis Testing .......................................... 117
9.5 Conducting a Statistical Test and Obtaining a Test
   Statistic .................................................... 118
  9.6 The Independent Groups \( t \)-Test ............................ 118
    9.6.1 Degrees of Freedom .................................... 119
    9.6.2 Format of Results from an Independent
           Groups \( t \)-Test ......................................... 120
    9.6.3 The \( p \)-Value: Its Definition and Meaning .............. 121
    9.6.4 The \( p \)-Value and Hypothesis Testing .................... 122
    9.6.5 Two More Examples of Results from an
           Independent Groups \( t \)-Test .......................... 122
  9.7 The Dependent Measures \( t \)-Test ............................... 123
9.8 Analysis of Variance ......................................... 125
9.9 One-Factor Independent Groups ANOVA ....................... 125
  9.9.1 The Test Statistic in ANOVA ................................. 126
  9.9.2 Calculation of the \( F \)-Test ................................ 126
  9.9.3 A Further Analytical Step: Multiple
           Comparisons ............................................. 128
  9.10 General Comments on Multiple-Comparison Testing ............ 130
  9.10.1 Type I Errors and Type II Errors ......................... 130
9.11 Possible Clinical Interpretations of Statistical Results ........ 132

10 Clinical Significance .......................................... 135
10.1 Introduction .................................................. 135
10.2 The Logic of Confidence Intervals ............................. 135
10.3 Confidence Intervals for a Sample Mean ....................... 136
  10.3.1 A More Precise Definition of a Confidence
           Interval .................................................. 137
10.4 Confidence Intervals for the Difference Between
    Treatment Group Means ...................................... 137
10.5 Relationship of the 95% CI and 99% CI to the 0.05 and
    0.01 \( p \)-Values ............................................ 138
10.6 The Additional Benefit of Using Confidence Intervals ............ 139
  10.6.1 Clinical Relevance and Clinically Relevant
           Differences .............................................. 139
11 Sample Size Estimation ........................................ 143
  11.1 Introduction ........................................... 143
  11.2 Ethical Issues in Sample Size Estimation ............ 144
  11.3 Variables Involved in Sample Size Estimation ......... 145
  11.4 Type I and Type II Errors .......................... 146
    11.4.1 The Implications of Type I and Type II Errors... 146
  11.5 Choosing the Variables Needed for Sample Size Estimation ........................................ 147
    11.5.1 Alpha and Beta .................................. 147
    11.5.2 The Treatment Effect, Its Variance, and the Standardized Treatment Effect ............ 148
  11.6 Using the Appropriate Formula to Yield the Sample Size ........................................ 148
  11.7 Influences on the Sponsor’s Choice of These Values ........................................... 149
  11.8 Choosing the Objective(s) on Which to Base the Sample Size Estimation ..................... 150
  11.9 Other Issues to Keep in Mind ...................... 150

12 General Safety Assessments ................................ 153
  12.1 Introduction ........................................... 153
  12.2 Operationalizing the Term Drug Safety .............. 153
    12.2.1 Perspectives of Regulators and Prescribing Physicians on Safety Data ................ 154
  12.3 General Safety Assessments .......................... 155
    12.3.1 Extent of Exposure ................................ 156
    12.3.2 Adverse Events .................................. 156
    12.3.3 Common Laboratory Tests ....................... 157
    12.3.4 Vital Signs ...................................... 159
  12.4 Acquisition and Management of Safety Data ........... 159
    12.4.1 Adverse Events .................................. 159
    12.4.2 Serious Adverse Event Data .................... 160
  12.5 Analysis Populations ................................... 161
  12.6 Presentation of Safety Data .......................... 161
    12.6.1 Descriptive Approaches to Safety Data .......... 162
    12.6.2 Time-to-Event Analysis ......................... 163
    12.6.3 Differences Between Approaches to Safety and Efficacy Data ..................... 164
Further Readings ........................................... 164

13 Efficacy Assessment ......................................... 165
  13.1 Introduction ........................................... 165
    13.1.1 Superiority, Equivalence, and Noninferiority Trials ....................................... 165
    13.1.2 Group Sequential and Adaptive Study Designs ........ 166
  13.2 Analysis Populations ................................... 166
    13.2.1 The Intent-to-Treat Population ................. 167
    13.2.2 The Per-protocol Population .................... 167
13.2.3 Using Both Analysis Populations ............ 167
13.2.4 Missing Data .................................. 168

13.3 Hypothesis Testing Is Integral to All of the Designs
Discussed ........................................... 168

13.4 Superiority Trials .................................. 169
13.4.1 Well-Defined Study Objectives and Endpoints ... 169
13.4.2 Analysis of Covariance .......................... 170
13.4.3 Subgroup Analysis ............................... 171

13.5 Equivalence Trials ................................ 172
13.5.1 Why the Hypothesis Testing Strategy Is
   Different Here ...................................... 173
13.5.2 Establishing the Equivalence Margin .......... 174
13.5.3 Hypothesis Construction and Testing ........... 175
13.5.4 Statistical Analysis and Clinical Judgment
   Working Together .................................. 176

13.6 Noninferiority Trials ............................... 176
13.6.1 Establishing the Noninferiority Margin .......... 176
13.6.2 Hypothesis Construction and Testing ............ 176
13.6.3 Statistical Analysis and Clinical Judgment
   Working Together .................................. 177

13.7 Group Sequential Designs ......................... 177
13.7.1 Interim Analyses in Group Sequential Trials .... 178
13.7.2 Data Monitoring Committees ..................... 178
13.7.3 Statistical Methodology for Interim Analysis .... 179
13.7.4 Ethical Considerations in Early Termination ..... 182

13.8 Adaptive Designs .................................. 183
13.8.1 Protocol Amendments ............................ 183
13.8.2 Increasing Awareness of Adaptive Designs ....... 184
13.8.3 Regulatory Guidance for Adaptive Designs ..... 185

13.9 Bayesian Approaches to Analyzing Clinical Trials .... 186

13.10 Meta-analysis ..................................... 186
13.10.1 Introduction to Meta-analysis .................. 187
13.10.2 The Basic Steps ................................. 188
13.10.3 Choice of the Summary Statistic
   Representing the Treatment Effect of Interest ....... 189
13.10.4 Data Analysis .................................. 189
13.10.5 Evaluating Robustness .......................... 191
13.10.6 Dissemination of Results and Conclusions
   of a Meta-analysis .................................. 191

13.11 Therapeutic Use Trials ............................ 192
13.11.1 Large Simple Therapeutic Trials ................ 192

Further Readings ..................................... 193

14 Cardiac and Cardiovascular Safety Assessments ............. 195
14.1 Introduction ....................................... 195
14.2 A Three-Component Risk Exclusion Model ............. 196
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.2.1</td>
<td>Confidence Intervals Facilitate the Determination of Thresholds of Regulatory Concern</td>
<td>197</td>
</tr>
<tr>
<td>14.3</td>
<td>Cardiac Safety Assessment: A Brief History</td>
<td>198</td>
</tr>
<tr>
<td>14.4</td>
<td>Obtaining QTc Data from QT Measurements</td>
<td>199</td>
</tr>
<tr>
<td>14.5</td>
<td>The Thorough QT/QTc Study</td>
<td>200</td>
</tr>
<tr>
<td>14.5.1</td>
<td>Design of the TQT Study</td>
<td>200</td>
</tr>
<tr>
<td>14.5.2</td>
<td>TQT Study Conduct</td>
<td>201</td>
</tr>
<tr>
<td>14.5.3</td>
<td>Statistical Analysis</td>
<td>202</td>
</tr>
<tr>
<td>14.5.4</td>
<td>Ramifications of Interpretations by Sponsors and Regulatory Agencies</td>
<td>203</td>
</tr>
<tr>
<td>14.6</td>
<td>FDA Guidance on Excluding Unacceptable Cardiovascular Risk in the Development of Antidiabetic Drugs for Type 2 Diabetes Mellitus</td>
<td>204</td>
</tr>
<tr>
<td>14.6.1</td>
<td>Clinical Trials to Be Conducted</td>
<td>204</td>
</tr>
<tr>
<td>14.6.2</td>
<td>Choice of Subject Populations</td>
<td>205</td>
</tr>
<tr>
<td>14.6.3</td>
<td>Choice of Cardiovascular Endpoints</td>
<td>205</td>
</tr>
<tr>
<td>14.6.4</td>
<td>Endpoint Adjudication</td>
<td>205</td>
</tr>
<tr>
<td>14.6.5</td>
<td>The Required Meta-analysis</td>
<td>206</td>
</tr>
<tr>
<td>14.6.6</td>
<td>A Dedicated Large (Simple) Cardiovascular Trial</td>
<td>207</td>
</tr>
<tr>
<td>14.6.7</td>
<td>An Additional Consideration for Safety Meta-analyses</td>
<td>208</td>
</tr>
<tr>
<td>14.7</td>
<td>An Example of a Real Safety Meta-analysis</td>
<td>208</td>
</tr>
<tr>
<td>14.8</td>
<td>Potential Regulatory Thresholds of Interest for Other Cardiovascular Parameters</td>
<td>209</td>
</tr>
<tr>
<td>Further Readings</td>
<td>210</td>
<td></td>
</tr>
</tbody>
</table>

**15 Manufacturing Small Molecule Drugs and Biologicals** | 211

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.1</td>
<td>Introduction</td>
<td>211</td>
</tr>
<tr>
<td>15.2</td>
<td>Nonclinical Development</td>
<td>212</td>
</tr>
<tr>
<td>15.3</td>
<td>Drug Products for Clinical Trials</td>
<td>212</td>
</tr>
<tr>
<td>15.3.1</td>
<td>Need for the Investigative Drug and the Control Drug</td>
<td>213</td>
</tr>
<tr>
<td>15.3.2</td>
<td>Blinding of Drug Products for Clinical Trials</td>
<td>213</td>
</tr>
<tr>
<td>15.3.3</td>
<td>Packaging and Distributing Clinical Drug Products</td>
<td>214</td>
</tr>
<tr>
<td>15.4</td>
<td>Commercial Manufacturing</td>
<td>215</td>
</tr>
<tr>
<td>15.5</td>
<td>Quality Control: Building Quality into the Process</td>
<td>215</td>
</tr>
<tr>
<td>15.6</td>
<td>Stability Studies</td>
<td>216</td>
</tr>
<tr>
<td>15.7</td>
<td>Immediate Release and Modified Release Tablets and Capsules</td>
<td>216</td>
</tr>
<tr>
<td>15.8</td>
<td>Recombinant Protein Biologicals</td>
<td>217</td>
</tr>
<tr>
<td>15.8.1</td>
<td>Commercial-Scale Manufacturing</td>
<td>218</td>
</tr>
<tr>
<td>Further Readings</td>
<td>219</td>
<td></td>
</tr>
</tbody>
</table>
16 Postmarketing Surveillance ............................................. 221
  16.1 Introduction ...................................................... 221
  16.2 Limitations of Preapproval Clinical Trials .................. 222
  16.3 Individual Differences in Drug Response .................... 223
    16.3.1 Hepatic Impairment ........................................ 223
    16.3.2 Renal Insufficiency ....................................... 224
    16.3.3 The Elderly ................................................. 224
    16.3.4 Pediatric Populations ..................................... 225
  16.4 Postmarketing Surveillance ..................................... 226
  16.5 The 2005 CDER Report to the Nation ......................... 227
  16.6 The Institute of Medicine’s 2006 Report on Drug Safety ..... 228
  16.7 The Food and Drug Administration Amendments Act of 2007 ......................................................... 229
  16.8 The FDA’s 2008 Sentinel Initiative ......................... 230
    16.8.1 The Science of Safety .................................... 230
    16.8.2 Active Surveillance ....................................... 231
Further Readings ......................................................... 231

17 Main Themes and Concluding Comments ............................ 233
  17.1 Introduction ...................................................... 233
  17.2 Ethical Considerations ......................................... 234
  17.3 Design, Methodology, Operations, and Analysis ............. 235
    17.3.1 Reducing Bias and Improving Precision ................ 235
    17.3.2 Our Definition of Statistics Revisited ................ 236
    17.3.3 Numerical Representations of Biological Information ........................................... 236
    17.3.4 Some Thoughts on the $p$-Value ......................... 237
  17.4 Confidence Intervals and Clinical Significance ............. 238
  17.5 Pharmacokinetics and Pharmacodynamics ..................... 238
  17.6 Decision-Making .................................................. 239
    17.6.1 The Subjective Nature of Many Decisions ............. 239
    17.6.2 Determining Thresholds of Regulatory Concern ......... 241
  17.7 Benefit–Risk Considerations .................................... 241
  17.8 Biological Considerations Pervade Our Discussions ........ 241
    17.8.1 Biological Underpinnings of Precision Medicine ..... 242
    17.8.2 Pharmacogenetics ........................................... 242
    17.8.3 Pharmacogenomics .......................................... 243
    17.8.4 Pharmacoproteomics ........................................ 243
  17.9 Integrated Pharmaceutical Medicine ........................... 244
  17.10 Concluding Comments .......................................... 245

References ................................................................. 247

Index .............................................................. 251
New Drug Development
An Introduction to Clinical Trials: Second Edition
Turner, J.R.
2010, XXV, 256 p., Hardcover